查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1682149

2025年全球先天性橫膈疝氣藥物市場報告

Congenital Diaphragmatic Hernia Drugs Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年先天性橫膈疝氣治療市場規模將強勁成長。到 2029 年，這一數字將成長至 63.3 億美元，年複合成長率（CAGR）為 7.5%。預測期內的成長歸因於醫療保健支出的增加、罕見疾病激勵措施、患者權益團體的增加、再生醫學、標靶治療等。預測期內的主要趨勢包括醫學研究的進步、藥物開發的進步、胎兒手術的進步、藥理肺的成長、個人化醫療的使用增加、新型創新藥物輸送系統的開發以及數位健康技術。

預計出生缺陷率的上升將成為先天性膈疝氣治療藥物市場擴張的催化劑。先天性異常包括出生時存在的結構或功能異常，會對嬰兒的整體健康和發育產生重大影響。先天性橫膈疝氣的治療涉及產前篩檢、遺傳諮詢和標靶治療等綜合辦法。這些措施旨在降低與先天性橫膈疝氣相關的先天性異常的發病率，增加早期療育和個人化護理的可能性，並最終改善受影響個體的整體健康和生活品質。例如，總部設在美國的政府間組織世界衛生組織（WHO）在2023年3月報告稱，每年約有800萬嬰兒出生時患有先天缺陷，其中十分之九發生在中低收入國家。此外，據估計，全球每年約有 24 萬名新生兒在出生後 28 天內死於先天性殘疾。因此，先天性疾病盛行率的不斷上升推動了先天性橫膈疝氣治療市場的成長。

先天性橫膈疝氣（CDH）發病率的不斷上升預計將成為 CDH 治療市場成長的主要驅動力。 CDH 是一種出生缺陷，其特徵是橫膈膜（分隔胸腔和腹腔的肌肉）出現異常開口或孔洞。這些藥物有可能改善 CDH 患者的預後，包括改善肺功能和降低肺動脈高壓。例如，根據美國非營利學術醫療中心克利夫蘭診所的資料，截至 2022 年 10 月，每 2,500 至 3,500 個新生兒中約有 1 個患有 CDH。此外，據報道，70%至90%被診斷出患有CDH的嬰兒能夠存活。因此，先天性橫膈疝氣（CDH）發病率的不斷上升正在推動CDH治療藥物市場的擴張。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場－宏觀經濟情景，包括利率、通膨、地緣政治、新冠疫情、以及復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球先天性橫膈疝氣治療PESTEL分析（政治、社會、技術、環境、法律、促進因素、限制因素）
  • 最終用途產業分析
  • 全球先天性橫膈疝氣治療市場：成長率分析
  • 全球先天性橫膈疝氣藥物市場表現：規模與成長，2019-2024
  • 全球先天性橫膈疝氣藥物市場預測：2024-2029年及2034年規模與成長
  • 全球先天性橫膈疝氣藥物總目標市場（TAM）

第6章市場區隔

  • 全球先天性橫膈疝氣治療市場：依類型、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 後外側博格達萊克疝
  • 前莫爾乾疝
  • 食道裂孔疝
  • 全球先天性橫膈疝氣治療市場（依治療、績效及預測），2019-2024 年、2024-2029 年、2034 年
  • 體外膜氧合
  • 其他治療方法
  • 全球先天性橫膈疝氣治療藥物市場診斷、績效及預測（2019-2024年、2024-2029年及2034年）
  • 產前
  • 出生後
  • 全球先天性橫膈疝氣治療市場：依最終用戶、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 居家護理
  • 專科診所
  • 其他最終用戶
  • 全球先天性橫膈疝氣治療藥物市場：後外側Bochdalek疝氣細分市場，依類型、績效及預測，2019-2024年、2024-2029年、2034年
  • 手術介入
  • 針對症狀的藥物
  • 全球先天性橫膈疝氣治療市場、前莫爾乾疝氣細分市場、類型、績效及預測（2019-2024 年、2024-2029 年及 2034 年）
  • 手術介入
  • 針對症狀的藥物
  • 全球先天性橫膈疝氣治療市場，依食道裂孔疝氣細分，依類型、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 手術介入
  • 製藥

第7章 區域和國家分析

  • 全球先天性橫膈疝氣治療市場：依地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球先天性橫膈疝氣治療市場：依國家/地區、績效及預測（2019-2024 年、2024-2029 年及 2034 年）

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章競爭格局與公司概況

  • 先天性橫膈疝氣藥物市場：競爭格局
  • 先天性橫膈疝氣藥物市場：公司簡介
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
    • Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

  • GlaxoSmithKline Plc
  • Medtronic plc
  • Amgen Inc.
  • Becton, Dickinson and Company
  • Viatris Inc.
  • B. Braun SE
  • Sun Pharmaceutical Industries Ltd.
  • CR Bard Inc.
  • WL Gore & Associates
  • Chiesi Farmaceutici SpA
  • Getinge AB
  • Ferring Pharmaceuticals
  • Mallinckrodt Pharmaceuticals
  • Integra LifeSciences Corporation
  • Genentech Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

  • 2029年先天性橫膈疝氣藥物市場：提供新機會的國家
  • 2029年先天性橫膈疝氣藥物市場：細分領域帶來新機會
  • 先天性橫膈疝氣治療市場 2029：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第36章 附錄

簡介目錄
Product Code: r27755

Congenital diaphragmatic hernia (CDH) is a rare condition characterized by a hole in the diaphragm, the muscular partition that separates the chest from the abdomen. Drugs designed for the treatment of Congenital diaphragmatic hernia (CDH) are medications intended to alleviate the severity of the condition, manage its symptoms, and address associated complications.

The primary categories of drugs for congenital diaphragmatic hernia include posterolateral Bochdalek hernia, anterior Morgagni hernia, and hiatal hernia. Posterolateral Bochdalek hernia, for example, is a specific form of congenital diaphragmatic hernia where a defect in the rear part of the diaphragm allows abdominal organs to enter the chest cavity. Treatment options vary, including extracorporeal membrane oxygenation (ECMO), and they can be administered during both prenatal and postnatal phases. These medications and treatments cater to a range of end-users, including hospitals, homecare settings, specialty clinics, and others.

The congenital diaphragmatic hernia drugs market research report is one of a series of new reports from The Business Research Company that provides congenital diaphragmatic hernia drugs market statistics, including congenital diaphragmatic hernia drugs industry global market size, regional shares, competitors with a congenital diaphragmatic hernia drugs market share, detailed congenital diaphragmatic hernia drugs market segments, market trends and opportunities and any further data you may need to thrive in the congenital diaphragmatic hernia drugs industry. This congenital diaphragmatic hernia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The congenital diaphragmatic hernia drugs market size has grown strongly in recent years. It will grow from $4.38 billion in 2024 to $4.73 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to high incidence of congenital diaphragmatic hernia cases, increasing awareness of congenital diaphragmatic hernia, government initiatives.

The congenital diaphragmatic hernia drugs market size is expected to see strong growth in the next few years. It will grow to $6.33 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to growing healthcare expenditure, rare disease incentives, growing patient advocacy groups, regenerative medicine, targeted therapies. Major trends in the forecast period include advancements in medical research, advancements in drug development, advances in fetal surgery, pharmacological lung growth, increasing use of personalized medicine, development of new and innovative drug delivery systems, digital health technologies.

The increasing rate of birth defects is expected to act as a catalyst for the expansion of the congenital diaphragmatic hernia drug market. Birth defects encompass structural or functional anomalies present at birth that can significantly impact a baby's overall health and development. Treatment for congenital diaphragmatic hernia involves a comprehensive approach that includes prenatal screening, genetic counseling, and targeted therapies. These measures are designed to reduce the occurrence of birth defects associated with congenital diaphragmatic hernia and enhance the potential for early intervention and personalized care, ultimately improving the overall well-being and quality of life for affected individuals. For example, in March 2023, the World Health Organization (WHO), an intergovernmental organization based in the US, reported that approximately 8 million infants are born with birth defects each year, with low- and middle-income countries accounting for nine out of every ten significant cases. Moreover, an estimated 240,000 newborns worldwide succumb to congenital disorders within 28 days of birth annually. Consequently, the increasing prevalence of birth defects serves as a driving force behind the congenital diaphragmatic hernia drug market's growth.

The increasing occurrence of congenital diaphragmatic hernia (CDH) is poised to be a significant driver for the growth of the congenital diaphragmatic hernia drug market. CDH is a congenital birth defect characterized by an abnormal opening or hole in the diaphragm, the muscle that separates the chest cavity from the abdominal cavity. These drugs have the potential to yield improved outcomes for CDH patients, including enhanced lung function and a reduction in pulmonary hypertension. For instance, as of October 2022, data from the Cleveland Clinic, a non-profit academic medical center based in the United States, indicates that CDH occurs in approximately 1 in 2,500 to 3,500 live births. Reports further suggest that a notable proportion of infants diagnosed with CDH, ranging from 70% to 90%, achieve survival. Consequently, the increasing incidence of congenital diaphragmatic hernia (CDH) serves as a driving force behind the expansion of the congenital diaphragmatic hernia drug market.

The leading companies in the congenital diaphragmatic hernia (CDH) market are at the forefront of introducing cutting-edge treatment innovations through the application of coating technology to maintain their market presence. This novel approach involves the utilization of coating technology for synthetic hernia mesh embedded with drugs, enhancing the treatment landscape. The coating technology entails the application of a specialized layer onto the surface of synthetic mesh used in hernia repair procedures. For example, in April 2022, Ariste Medical, a pre-commercial drug and device company based in the United States, received clearance from the U.S. Food and Drug Administration (FDA) to market its drug-embedded synthetic hernia mesh. This innovative mesh is designed to mitigate the risk of microbial colonization during surgical implantation by combining the advantages of polypropylene mesh with a biocompatible coating that supports antibiotic residency. This versatile coating technology holds promise for both implantable and non-implantable medical devices and exhibits potential applications in materials like polyurethane and ePTFE. Furthermore, Ariste Medical's coating technology has the potential to revolutionize ePTFE surgical implants, including those used in hernia repair surgeries.

In May 2023, Juno Pharmaceuticals, a Canada-based pharmaceutical company, acquired Omega Laboratories Inc. for an undisclosed amount. This acquisition establishes Juno as the largest specialty generic injectable business in Canada, expanding its capabilities in improving drug supply within the sector. The merger is aimed at enhancing access to essential injectable medications, significantly strengthening Juno's position in the specialty pharmaceutical industry. Omega Laboratories Inc., based in the United States, specializes in drug testing and produces medications that aid in the management of conditions related to congenital diaphragmatic hernia. This strategic acquisition is expected to bolster Juno's market share and diversify its portfolio of specialty pharmaceuticals.

Major companies operating in the congenital diaphragmatic hernia drugs market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Amgen Inc., Becton, Dickinson and Company, Viatris Inc., B. Braun SE, Sun Pharmaceutical Industries Ltd., C.R. Bard Inc., W. L. Gore & Associates, Chiesi Farmaceutici S.p.A., Getinge AB, Ferring Pharmaceuticals, Mallinckrodt Pharmaceuticals, Integra LifeSciences Corporation, Genentech Inc., LifeCell International Private Limited, Cook Biotech Inc., Cousin Biotech SAS, Dipro Medical Devices S.R.L., Aspide Medical.

North America was the largest region in the congenital diaphragmatic hernia drugs market in 2024. The regions covered in congenital diaphragmatic hernia drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the congenital diaphragmatic hernia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The congenital diaphragmatic hernia drugs market consists of revenues earned by entities by providing surgical treatments and medical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The congenital diaphragmatic hernia drug market also includes sales of pain management medications, antibiotics, vasoactive agents, dobutamine and milrinone. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Congenital Diaphragmatic Hernia Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on congenital diaphragmatic hernia drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for congenital diaphragmatic hernia drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The congenital diaphragmatic hernia drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Posterolateral Bochdalek Hernia; Anterior Morgagni Hernia; Hiatal Hernia
  • 2) By Treatment: Extracorporeal Membrane Oxygenation; Other Treatments
  • 3) By Diagnosis: Prenatal; Postnatal
  • 4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End Users
  • Subsegments:
  • 1) By Posterolateral Bochdalek Hernia: Surgical Interventions; Medications for Symptoms
  • 2) By Anterior Morgagni Hernia: Surgical Interventions; Medications for Symptoms
  • 3) By Hiatal Hernia: Surgical Interventions; Medications
  • Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; Merck and Co. Inc.; AbbVie Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Congenital Diaphragmatic Hernia Drugs Market Characteristics

3. Congenital Diaphragmatic Hernia Drugs Market Trends And Strategies

4. Congenital Diaphragmatic Hernia Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Congenital Diaphragmatic Hernia Drugs Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Congenital Diaphragmatic Hernia Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Congenital Diaphragmatic Hernia Drugs Market Growth Rate Analysis
  • 5.4. Global Congenital Diaphragmatic Hernia Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Congenital Diaphragmatic Hernia Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Congenital Diaphragmatic Hernia Drugs Total Addressable Market (TAM)

6. Congenital Diaphragmatic Hernia Drugs Market Segmentation

  • 6.1. Global Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Posterolateral Bochdalek Hernia
  • Anterior Morgagni Hernia
  • Hiatal Hernia
  • 6.2. Global Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Extracorporeal Membrane Oxygenation
  • Other Treatments
  • 6.3. Global Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Prenatal
  • Postnatal
  • 6.4. Global Congenital Diaphragmatic Hernia Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End Users
  • 6.5. Global Congenital Diaphragmatic Hernia Drugs Market, Sub-Segmentation Of Posterolateral Bochdalek Hernia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Surgical Interventions
  • Medications for Symptoms
  • 6.6. Global Congenital Diaphragmatic Hernia Drugs Market, Sub-Segmentation Of Anterior Morgagni Hernia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Surgical Interventions
  • Medications for Symptoms
  • 6.7. Global Congenital Diaphragmatic Hernia Drugs Market, Sub-Segmentation Of Hiatal Hernia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Surgical Interventions
  • Medications

7. Congenital Diaphragmatic Hernia Drugs Market Regional And Country Analysis

  • 7.1. Global Congenital Diaphragmatic Hernia Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Congenital Diaphragmatic Hernia Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Congenital Diaphragmatic Hernia Drugs Market

  • 8.1. Asia-Pacific Congenital Diaphragmatic Hernia Drugs Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Congenital Diaphragmatic Hernia Drugs Market

  • 9.1. China Congenital Diaphragmatic Hernia Drugs Market Overview
  • 9.2. China Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Congenital Diaphragmatic Hernia Drugs Market

  • 10.1. India Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Congenital Diaphragmatic Hernia Drugs Market

  • 11.1. Japan Congenital Diaphragmatic Hernia Drugs Market Overview
  • 11.2. Japan Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Congenital Diaphragmatic Hernia Drugs Market

  • 12.1. Australia Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Congenital Diaphragmatic Hernia Drugs Market

  • 13.1. Indonesia Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Congenital Diaphragmatic Hernia Drugs Market

  • 14.1. South Korea Congenital Diaphragmatic Hernia Drugs Market Overview
  • 14.2. South Korea Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Congenital Diaphragmatic Hernia Drugs Market

  • 15.1. Western Europe Congenital Diaphragmatic Hernia Drugs Market Overview
  • 15.2. Western Europe Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Congenital Diaphragmatic Hernia Drugs Market

  • 16.1. UK Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Congenital Diaphragmatic Hernia Drugs Market

  • 17.1. Germany Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Congenital Diaphragmatic Hernia Drugs Market

  • 18.1. France Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Congenital Diaphragmatic Hernia Drugs Market

  • 19.1. Italy Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Congenital Diaphragmatic Hernia Drugs Market

  • 20.1. Spain Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Congenital Diaphragmatic Hernia Drugs Market

  • 21.1. Eastern Europe Congenital Diaphragmatic Hernia Drugs Market Overview
  • 21.2. Eastern Europe Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Congenital Diaphragmatic Hernia Drugs Market

  • 22.1. Russia Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Congenital Diaphragmatic Hernia Drugs Market

  • 23.1. North America Congenital Diaphragmatic Hernia Drugs Market Overview
  • 23.2. North America Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Congenital Diaphragmatic Hernia Drugs Market

  • 24.1. USA Congenital Diaphragmatic Hernia Drugs Market Overview
  • 24.2. USA Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Congenital Diaphragmatic Hernia Drugs Market

  • 25.1. Canada Congenital Diaphragmatic Hernia Drugs Market Overview
  • 25.2. Canada Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Congenital Diaphragmatic Hernia Drugs Market

  • 26.1. South America Congenital Diaphragmatic Hernia Drugs Market Overview
  • 26.2. South America Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Congenital Diaphragmatic Hernia Drugs Market

  • 27.1. Brazil Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Congenital Diaphragmatic Hernia Drugs Market

  • 28.1. Middle East Congenital Diaphragmatic Hernia Drugs Market Overview
  • 28.2. Middle East Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Congenital Diaphragmatic Hernia Drugs Market

  • 29.1. Africa Congenital Diaphragmatic Hernia Drugs Market Overview
  • 29.2. Africa Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Congenital Diaphragmatic Hernia Drugs Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Congenital Diaphragmatic Hernia Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Congenital Diaphragmatic Hernia Drugs Market Competitive Landscape
  • 30.2. Congenital Diaphragmatic Hernia Drugs Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Congenital Diaphragmatic Hernia Drugs Market Other Major And Innovative Companies

  • 31.1. GlaxoSmithKline Plc
  • 31.2. Medtronic plc
  • 31.3. Amgen Inc.
  • 31.4. Becton, Dickinson and Company
  • 31.5. Viatris Inc.
  • 31.6. B. Braun SE
  • 31.7. Sun Pharmaceutical Industries Ltd.
  • 31.8. C.R. Bard Inc.
  • 31.9. W. L. Gore & Associates
  • 31.10. Chiesi Farmaceutici S.p.A.
  • 31.11. Getinge AB
  • 31.12. Ferring Pharmaceuticals
  • 31.13. Mallinckrodt Pharmaceuticals
  • 31.14. Integra LifeSciences Corporation
  • 31.15. Genentech Inc.

32. Global Congenital Diaphragmatic Hernia Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Congenital Diaphragmatic Hernia Drugs Market

34. Recent Developments In The Congenital Diaphragmatic Hernia Drugs Market

35. Congenital Diaphragmatic Hernia Drugs Market High Potential Countries, Segments and Strategies

  • 35.1 Congenital Diaphragmatic Hernia Drugs Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Congenital Diaphragmatic Hernia Drugs Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Congenital Diaphragmatic Hernia Drugs Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer